Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Double-Blind, Saline-Controlled, Randomized Study to Evaluate the Safety and Preliminary Efficacy of a Single Dose Intradiscal Injection of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)

Next Previous
Trial Profile

A Phase 2, Double-Blind, Saline-Controlled, Randomized Study to Evaluate the Safety and Preliminary Efficacy of a Single Dose Intradiscal Injection of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BRTX 100 (Primary)
  • Indications Back pain; Intervertebral disc degeneration
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors BioRestorative Therapies

Most Recent Events

  • 13 Jun 2025 According to a BioRestorative Therapies media release, preliminary blinded data from the first 36 subjects in its ongoing Phase 2 clinical trial of BRTX-100 were presented at the prestigious The International Society for Stem Cell Research (ISSCR) 2025 Annual Meeting in Hong Kong by Francisco Silva, Vice President of Research and Development.
  • 13 Jun 2025 Results presented in a BioRestorative Therapies Media Release.
  • 09 Jun 2025 According to a BioRestorative media release, new preliminary, blinded clinical data from 30 patients enrolled in this trial ss will be presented at the prestigious International Society for Stem Cell Research (ISSCR) 2025 Annual Meeting

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top